Peptide research evidence, stack analysis & UK regulatory context
Evidence-led summaries of peptide combinations, mechanisms, study models, safety uncertainties and translational limitations. Not dosing advice, not medical advice, and not a protocol for human or animal use.
Educational research-literacy content only. PeptideStacks summarises published evidence, mechanisms, study models, regulatory context and translational limitations for peptide-related research. It does not provide medical advice, dosing recommendations, sourcing advice, self-administration instructions, or protocols for human or animal use. See our medical disclaimer and responsible information policy.
Explore the platform
25 peptide monographs · 21 stack evidence reviews · 8 comparisons · seven research and regulatory hubs.
Stack evidence reviews
Combination evidence with conservative grading and direct-vs-inferred labelling.
Peptide monographs
Per-peptide evidence summaries — mechanism, human-data status, regulatory context.
Evidence grading A–X
How we grade strength of evidence — conservatively, by default.
UK regulation hub
MHRA, POM advertising, research chemicals vs medicines, anti-doping.
Safety & quality hub
Contamination, sterility, immunogenicity, counterfeit supply chains.
Mechanism maps
GH axis, angiogenesis, NF-κB, AMPK, melanocortin, incretin & more.
Claim red flags
Marketing patterns, fake citation tactics, synergy that wasn’t demonstrated.
Research tools
Evidence strength checker, regulatory classifier, PubMed search builder.
Featured stack evidence reviews
Each review carries an evidence dashboard — grade, human-data status, direct-vs-inferred combination evidence, translational risk, and regulatory sensitivity.
BPC-157 + TB-500 + GHK-Cu — Research Evidence Review: Tissue-Repair & Remodelling Mechanisms
Three-peptide advanced soft tissue + dermal remodelling research stack. Adds GHK-Cu copper peptide to the canonical BPC-157/TB-500 base for collagen-I:III ratio improvement.
BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits
The most-studied tissue-repair peptide combination — BPC-157 with TB-500. Mechanisms, summarised studies, full dosing table, weekly timeline and UK regulatory note.
CJC-1295 + Ipamorelin + Tesamorelin — Research Evidence Review: GH Axis Mechanisms & Study Limitations
Synergistic GHRH + GHRP + GHRH-analog research stack for the somatotropic axis. Mechanism, dosing, timing and UK regulatory notes.
Epitalon + Humanin + MOTS-c — Research Evidence Review: Mitochondrial & Telomeric Mechanisms
Three-peptide longevity research stack targeting telomerase activation, mitochondrial unfolded-protein response and metabolic ageing. Full dosing protocol and UK regulatory note.
KPV + LL-37 — Research Evidence Review: Mucosal & Antimicrobial Mechanisms
KPV α-MSH tripeptide and the human cathelicidin LL-37 — an immunomodulatory + antimicrobial peptide stack studied for intestinal mucosal research.
Semax + Selank + Pinealon — Research Evidence Review: Neuropeptide Mechanisms & Translational Limits
Russian-origin neuropeptide nootropic research stack — BDNF up-regulation, anxiolytic action and pineal cognition support. Full intranasal research protocol.
How to use this site responsibly
1. Read the evidence dashboard
Every page begins with a dashboard showing grade, human-data status, direct combination evidence, and translational risk.
2. Check for direct combination data
Most stacks are inferred from monotherapy literature. We say so explicitly when a combination has not been directly studied.
3. Review the regulatory context
Most compounds discussed here are not approved medicines in the UK. We describe the regulatory framework, we don't override it.
4. Do not treat a review as a protocol
Doses cited in study contexts are descriptive, not recommendations. PeptideStacks does not publish use protocols.
Conservative grades by default
Most peptide stacks on this site sit at Grade C or below. Combination evidence is rarely higher than the monotherapy evidence supporting either component.
UK regulatory clarity
Plain-English MHRA framing on every relevant page — including why ‘research use only’ is a label, not a legal carve-out.
Misinformation flagged
A whole hub of common claim patterns — fake citations, assumed synergy, before-and-after framing — and how to read past them.
Recent research syntheses
Editorial syntheses of the recent literature, with conservative framing and explicit limitations.
2026-05-21
Triple Incretin Agonism — Retatrutide and the GLP-1 / GIP / Glucagon Evidence Base
Critical research-literacy review of the GLP-1 / GIP / glucagon triple-agonist class — receptor pharmacology, Phase II trial evidence for retatrutide, comparison with tirzepatide, and the UK regulatory framing.
2026-05-21
Peptide Stacking Fundamentals — What 'Stack' Means in the Research Literature
An evidence-literacy introduction to what peptide stacking means in published research, when combination evidence is direct vs inferred, and how to read a stack page on PeptideStacks responsibly.
2026-05-21
BPC-157 + TB-500 — A Critical Review of the Combination Evidence
Critical review of the published in vitro and animal-model studies examining BPC-157 and TB-500 together — what the literature shows, what it doesn't, and where the replication gaps sit.
Trust & transparency
Frequently asked questions
Is this medical advice?
No. PeptideStacks publishes evidence summaries for research literacy. For health concerns, consult a registered clinician.
Do you provide dosing protocols?
No. We describe doses reported in published studies for descriptive context. We do not publish recommended doses, cycles, or use protocols.
Are peptides legal in the UK?
It depends on the compound, the supply context, and the claims made. Many peptides are unapproved medicines in the UK. See our regulation hub.
What does 'research use only' actually mean?
It's a labelling convention for laboratory reagents. It does not override UK medicines law and is not authorisation for human use.
How are evidence grades assigned?
Conservatively, by default. Most stacks sit at Grade C or lower because combination evidence is rarely robust. See our methodology page.
Why don't animal studies prove a human effect?
Translation from animal models to humans fails the majority of the time. Animal evidence is mechanism-suggestive, not human-relevant.
Evidence updates, monthly
When the evidence base on a peptide or combination changes — new trial data, regulatory updates, safety signals — we add a changelog entry. Subscribe for the digest.
Sister sites & sponsor
Paid sponsorPeptideAuthority.co.uk
Per-peptide research monographs — companion long-form reference.
PeptideBarn.co.ukSponsor
UK research-grade peptide supply — for laboratory use only.
Editorial independent — see our conflict-of-interest disclosure.
Comparisons
Side-by-side evidence comparisons of peptides discussed together in research and online — mechanisms, evidence, regulatory status, safety uncertainty.
Browse all comparisons